期刊
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL
卷 15, 期 6, 页码 162-172出版社
CANADIAN UROLOGICAL ASSOCIATION
DOI: 10.5489/cuaj.7268
关键词
-
PSMA-targeted PET is increasingly used for prostate cancer detection globally, with high accuracy for biochemical failure and initial disease staging, but its role in metastatic disease is less clear. Familiarity with potential pitfalls in interpretation is crucial for accurate diagnosis.
Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) is increasingly being used worldwide as part of the clinical workup for men with prostate cancer. With high overall accuracy for the detection of prostate cancer, PSMA-targeted PET has an increasingly established role in the setting of biochemical failure after primary therapy and an evolving role in the setting of initial disease staging; its utility for guiding management in the setting of metastatic disease is less clear. Although the specificity is high, familiarization with potential pitfalls in the interpretation of PSMA-targeted PET, including knowledge of the causes for false-positive and negative examinations, is critical. The aim of this best practice report is to provide an illustrative discussion of the current and evolving clinical indications for PSMA-targeted PET, as well as a review of physiological radiopharmaceutical biodistribution and potential imaging pitfalls.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据